This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 8-Point Plan for Higher Stock Prices

Implement these initiatives, said Cramer, and the stock market would rocket to all-time highs and America would be on a much more solid footing with a far brighter future.

Executive Decision

In the "Executive Decision" segment, Cramer spoke with Chris Garabedian, president and CEO of Sarepta Therapeutics (SRPT - Get Report), a small biotech firm that saw its shares soar over 200% after the company announced Wednesday positive data for its muscular dystrophy drug, Eteplirsen. Cramer recommended Sarepta as a speculative stock back on Sept. 21.

Garabedian said his company is very excited about today's news and the market's response to it, as well as what the data mean to patients and their families. He then showed a chart of how patients taking Eteplirsen fared against those taking a placebo over a 48-week period.

The data clearly showed those patients taking the placebo saw a steady progression of the disease until they were no longer able to walk, but those taking Eteplirsen not only stabilized but actually saw improvement in weeks 36 through 48. Sarepta has now switched those taking the placebo to Eteplirsen and is studying how the drug affects people in the later stages of the disease.

Garabedian explained that while the data only include Phase II results and the sample size was 12 patients, this is not uncommon for a rare disease. What matters most is how much patients improved while taking the drug. He also responded to criticisms that two patients did not respond to the drug. He said in those cases the disease had already started progressing before the drug could take hold.

Garabedian said Sarepta is amenable to taking on partners to help it speed up its Eteplirsen program and expand it overseas, but the company is also preparing to continue developing the drug in-house if necessary.

Cramer said results like these don't come from a paycheck, or a bank CD or even a typical stock, they only come from speculating, which is why he has always said that speculation needs to be a part of everyone's portfolio.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HPQ $29.18 4.18%
SRPT $37.81 -0.42%
VFC $71.33 2.38%
AAPL $109.50 -1.16%
FB $92.47 0.08%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs